The early-stage biotech IPO window now has a mechanism test

The IPO window is reopening to early-stage biotechs on a specific bet: a mechanism story can be sold before Phase 2 data. Attovia's S-1 sits in that batch with Kalohexis and Scribe Therapeutics — three filings where the asset is a target choice, not a de-risked readout.

The load-bearing claim is the receptor question. Attovia's lead, ATTO-1310, goes after the IL-31 itch-signaling ligand directly. Galderma's Nemluvio, the incumbent Attovia names, blocks the IL-31 receptor alpha downstream. In principle, catching the ligand at the source could produce a cleaner signal than blocking one of several receptors it feeds into. The seller of that critique is the company whose own peak-sales forecast just doubled past $4B.

The 65% pooled Week-4 responder rate Fierce Biotech reported from Attovia's Phase 1b, paired with 0% on placebo, is the kind of preliminary read such pitches live or die on: two dose cohorts, small n, company-reported, no peer review. A Phase 2 starting the first half of next year, with endpoints a reader can verify, is where the ligand-versus-receptor story has to hold up — or stop being a mechanism bet and start being S-1 marketing.